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FACTORS ASSOCIATED WITH PRESCRIPTION 
CLAIMS FOR BLOOD GLUCOSE TEST STRIPS 
AMONG FEE-FOR-SERVICE NEW MEXICO 
MEDICAID PATIENTS
Cordova CJ, Shah BM, Dodd MA, Gupchup GV
The University of New Mexico, Albuquerque, NM, USA
OBJECTIVE: Continuous blood glucose monitoring
which requires the use of blood glucose test strips (BGTS)
is essential for diabetes management. The objective of
this study was to identify predictors of claims for BGTS
submitted to the New Mexico Medicaid fee-for-service
(NMMFFS) program. METHODS: Patients with pre-
scription claims for insulin or oral diabetic medications
between December 1, 1999 and November 30, 2000
were identified from the NMMFFS claims database. It
was determined if these patients had claims for BGTS. In-
formation on demographic predictors including age, gen-
der, race/ethnicity, insulin use, and area of residence (ru-
ral, urban, intermediate) were extracted. A forward
stepwise logistic regression analysis using the likelihood-
ratio (LR) test, was performed to identify significant pre-
dictors of claims for BGTS. RESULTS: A total of 5636
diabetic patients, mean age 65.93 (SD  17.25), were
identified. Of these, 38.6% (n  2178) had claims for
BGTS. About 70% (n  3974) were female, 45.1% (n 
2543) had claims for insulin, and 38.8% (n  2185) re-
sided in an urban area. Additionally, there were 42.7%
(n  2408) non-Hispanic whites, 30.8% (n  1738) His-
panics, and 9.2% (n  519) American Indians. The logis-
tic regression results indicated that younger patients (OR
 0.97, 95% CI  0.97–0.98) and patients with claims
for insulin (OR  1.88, 95%CI  1.68–2.11) were more
likely to have claims for BGTS. However, males (OR 
0.64, 95% CI  0.56–0.73), patients who lived in inter-
mediate areas (OR  0.74, 95% CI  0.65–0.83), non-
Hispanic whites (OR  0.78, 95% CI  0.67–0.91), His-
panics (OR  0.63, 95% CI  0.53–0.75) and American
Indians (OR  0.40, 95% CI  0.32–0.51) were all less
likely to have claims for BGTS. CONCLUSIONS: Elderly
patients who are female, non-insulin users, non-Hispanic
white, Hispanic or American Indian and live in interme-
diate areas are less likely to have claims for strips. There-
fore, educational interventions are needed to increase
claims for BGTS in these patients, thus improving blood
glucose monitoring.
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COST-EFFECTIVENESS ANALYSIS OF A 
MULTIDISCIPLINARY DIABETES CARE CLINIC
Yokoyama KK, Griffin KC, Godley PJ, Cryar AK,
Woodward BW
Scott & White Memorial Hospital, Temple, TX, USA
OBJECTIVES: Diabetes affects more than 15.7 million
people in the United States, resulting in an estimated an-
nual cost of $98 billion (1997). With numerous compli-
cations, including heart disease, retinopathy, nephropa-
thy, and neuropathy, contributing to the direct and
indirect costs of diabetes, control is vital. A cost-effective-
ness analysis was performed to compare health care re-
source utilization related to diabetes care incurred by
health plan patients. METHODS: Subjects were enrolled
in the Diabetes Care Clinic (DCC) for at least one year
and were members of the health plan for one year prior
to enrollment. Pharmacy and medical claims data from
1997–2000 were analyzed to identify diabetes-related
charges incurred one year pre- and post-enrollment in the
DCC. Charges were used to estimate costs and were ad-
justed to year 2000 dollars at a rate of inflation of 3%.
Using the electronic medical record and clinic charts, he-
moglobin A1c (HgbA1c), cholesterol profile, microalbu-
minuria, and blood pressure were evaluated. RESULTS:
23 diabetic patients met the inclusion criteria. These pa-
tients were mostly Type 2 diabetics (91%), female
(65%), and Caucasian (70%). The mean age was 58
years. A preliminary analysis of the data indicated that
the average HgbA1c decreased from 10.3 to 8.5, with 9
patients attaining glycemic control (defined as HgbA1c 
8.0) after one year of enrollment. Additionally, average
blood pressure decreased from 152/80 to 136/73. The av-
erage annual cost per patient for diabetes-related care
was $3,090 pre-enrollment and $4,760 post-enrollment.
A marginal cost-effectiveness ratio, in terms of cost to
number of patients attaining glycemic control, was calcu-
lated. The added cost for glycemic control of one patient
was $186. CONCLUSIONS: An analysis of short-term
outcomes demonstrated the cost-effectiveness of a diabe-
tes care clinic. By maintaining tight glycemic and blood
pressure control, diabetic complications can be reduced
with significant savings to the health plan.
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THE COST OF NEW ONSET DIABETES 
MELLITUS AMONG US RENAL
TRANSPLANT RECIPIENTS
Woodward RS1, Schnitzler MA1, Lowell JA1, Haider S2, 
Brennan DC1
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OBJECTIVES: Immunosuppressive medications are asso-
ciated with increased diabetes among kidney transplant
recipients. We used data from the USRDS database to es-
timate the incidence and the average cost to Medicare of
new onset diabetes Mellitus (NODM). METHODS: The
USRDS database merges the UNOS renal transplant reg-
istry with Medicare billing and payment records. The
USRDS registry recorded 9,541 single-organ, first, kidney
transplants in 1996; 5,987 (63%) of these were not dia-
betic at transplantation. For the 4,515 (75% of 5,987)
patients with Medicare claims, we merged all Medicare
institutional and physician supplier claims records from
1996 through 1997 with the clinical information from
UNOS. We classified patients as newly diabetic if any
